(Reuters Health)—Women who maintain an overall healthy diet may benefit from a slightly reduced risk of hip fractures later in life, according to a new U.S. study. Women who followed a Mediterranean-style diet were about three tenths of a percent less likely to break a hip over about 16 years, compared to women who didn’t…
Combination Therapy Bests Monotherapy in Severe Postmenopausal Osteoporosis
NEW YORK (Reuters Health)—The combination of denosumab and teriparatide improves bone microarchitecture and estimated strength more than either drug alone in women with severe postmenopausal osteoporosis, researchers have found. Dr. Joy Tsai, from Massachusetts General Hospital in Boston, and colleagues conducted a single-site, two-year, open-label, randomized controlled trial involving 94 women aged 45 or older…

2015 ACR/ARHP Annual Meeting: Genetic Links Emerge in Osteoarthritis
SAN FRANCISCO—As researchers have delved into the genetics behind osteoarthritis (OA), genes that appear to be players in the disease have emerged, but there have also been curveballs thrown, with expectations not always matching up to the genetic realities, an expert said at the 2015 ACR/ARHP Annual Meeting. The genetic risk of acquiring OA is…

2015 ACR/ARHP Annual Meeting: Research Lends Insight Into Osteoporosis Treatment, New Auto-Inflammatory Disease, Scleroderma
SAN FRANCISCO—Post-menopausal women with osteoporosis, previously treated with oral bisphosphonates, had greater increases in bone density when taking denosumab compared with zoledronic acid over a year’s time, according to a study presented at the 2015 ACR/ARHP Annual Meeting. The findings were discussed in the Discovery 2015 plenary session, which focused on new research. In the…
Routine Osteoporosis Screening in Men Proves Cost-Effective
NEW YORK (Reuters Health)—Routine osteoporosis screening in men is a good value and effective based on a cost-effectiveness model, researchers say. “Osteoporosis is not just a disease for women. Osteoporosis affects many men (approximately 2 million in the U.S.), with significant morbidity, mortality, and costs that are projected to rise with the aging of the…
Denosumab Does Not Stimulate Early Bone Formation
NEW YORK (Reuters Health)—The early elevation in intact parathyroid hormone (iPTH) seen with denosumab treatment is not associated with increased bone formation, according to research from Eli Lilly and Company. Denosumab is a member of the anticatabolic/antiresorptive class of drugs used to treat osteoporosis; iPTH levels are increased in the first several months after denosumab…
Amgen, UCB Say Osteoporosis Drug Meets Main Goal in Late-Stage Trial
(Reuters)—Amgen Inc. and Belgium-based UCB SA said on Monday that their osteoporosis drug met all the primary endpoints by reducing the incidence of new vertebral fracture in postmenopausal women with osteoporosis in a late-stage study. The topline results, from a Fracture study in postmenopausal women with osteoporosis (FRAME), showed that the drug romosozumab met a…

Study Targets Osteoclast Receptor to Inhibit Osteoclastogenesis
The results of a new study examined the human osteoclast-associated receptor may aid in the development of therapeutic matrikines to control aberrant osteoclastogenesis in some autoimmune diseases…
VA Musculoskeletal Education Pilot Program Helps PCPs Treat Patients
To improve access to quality of care for patients with osteoarthritis and other musculoskeletal pain, the U.S. Department of Veterans Affairs (VA) launched a continuing education program designed to strengthen the musculoskeletal knowledge and skills of primary care providers (PCPs). In the program’s initial trial in 2012, 19 physicians were trained on exams, treatments and joint injections. Two years after course completion, some participants increased the number of intraarticular corticosteroid injections at their clinics without needing to refer patients to specialists…
Rheumatology Coding Corner Questions: ICD-10 Coding Guidelines, Conventions Refresher Quiz Part 1
What is the ICD-10 guideline to code for osteoporosis without a current pathological fracture? There is no rule. Code for the osteoporosis, and code for the pathological fracture. Code for the osteoporosis from the M81._ category, and code for the history of a pathological fracture. None of the above is correct. How many characters are…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 46
- Next Page »